PET/CT Imaging in Prostate Cancer Patients

PYLARIFY Imaging in High-Risk Prostate Cancer

Video Library —February 1, 2022

Categories:

Interview with the Innovators
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Related Articles
Educating on HER2-Low mBC
Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG
|
Video Library
In this inaugural video, the panel provides peer-to-peer perspectives on educating the care team and patients on the new classification of HER2-low mBC.
Fostering Shared Treatment Decision-Making
Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG
|
Video Library
In this second installment, our expert panel suggests approaches to empowering patients to become involved in shared decision-making.
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, Emily Beard, RN, BSN, OCN, CBCN
|
Video Library
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512